We invite you to register for a 1,5 hour webinar called “Clinical Trial Update 2023”. The goal of the webinar is to update the OI-community about ongoing clinical trials – both those who are recruiting and others. This includes the following trials: – The Cosmic and the Orbit trials (setrusumab) – The BoostB4 trial (stem…
Physician statements on children with severe types of OI Dear colleague, In the literature there is very limited information on fracture incidence during the first years of life in children with OI type III and IV on early bisphosphonate treatment. We understand your busy schedule, but we would appreciate your quick input on the statement…
In Sweden, the Karolinska Institutet and the Karolinska University Hospital are leading the academic clinical trial BOOSTB4 where we are looking for subjects who have a diagnosis of OI Type III or severe Type IV with a specific collagen mutation. The aim of the clinical trial is to study the safety and efficacy of the…
Interview with Anne Siqveland and Nicolai Wendt (parents of Tellef, 1 year old) Who are you and what is your relationship to OI? We are a Norwegian family of four, Anne (36), Nicolai (34), Edvard (4) and Tellef (1). Tellef was prenatally diagnosed with OI and his multiple fractures and mutation of COL1A2 gene place…
For a number of years treatment of OI was mostly limited to bisphosphonates, surgical interventions and physiotherapy. Well basically it still is, if you think of approved and standardized treatment (if such a thing exists in OI). The group of drugs called bisphosphonates actually celebrates its 50th anniversary this year. And for the last 25-30…
Written by Eva Åström, member of OIFE Medical Advisory Board OI symposium in Vellore India The Centre for Stem Cell Research at the Christian Medical Collage in Vellore, India arranged a two day symposium on OI and stem cell treatment on the 6th – 7th of February 2019. The aim was to provide a platform…
